FDA Approves Targeted Therapy Combination for Melanoma


Just over a month after approving a first-of-its-kind combination therapy for advanced melanoma, the U.S. Food and Drug Administration (FDA) has signed off on another drug combination to treat the disease.

Skin cancer screeningsThe FDA has approved a targeted therapy combination, Cotellic (cobimetinib) and vemurafenib, to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery. The therapy targets a certain type of abnormal gene: BRAF V600E or V600K mutation.

“Treatment for melanoma is advancing at a record pace, with numerous new and exciting options for patients,” says Elizabeth Buchbinder, MD, a physician with Dana-Farber’s Melanoma Treatment Center. “The landscape for metastatic melanoma has been changing dramatically in a setting where there were previously only a few treatments available.”

In early October 2015, the FDA approved the first cancer treatment to combine two immunotherapy drugs: ipilimumab (Yervoy) and nivolumab (Opdivo). The immunotherapeutic combination has been approved to treat certain patients with unresectable or metastatic melanoma. Specifically, it is approved for patients who have tumors that do not harbor the BRAF V600 mutations found in about 50 percent of melanomas.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

Latest Tweets

Dana-Farber @danafarber
What’s the difference between basic, clinical and translational research? https://t.co/AUkZ2agb78 #cancerresearch https://t.co/iwwRqhDsYW
Dana-Farber @danafarber
While #skintags are not cancerous, it is important to keep an eye on any growths or changes in the skin. Learn more… https://t.co/ZJt7d5q0wJ
Dana-Farber @danafarber
TOMORROW: join us for a Facebook Live Q&A with Liz Farrell, LICSW, a social worker who counsels #breastcancer patie… https://t.co/i5Y8GcImYC

Patient and Family Blogs

Patients and families of patients at Dana-Farber often chronicle their own experiences with cancer.

Here are some blogs that you can follow.